Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

SA-9499 identified as potent and selective LTA4 hydrolase inhibitor at Santen

Nov. 27, 1998

Zileuton trials recommended for new indication: atopic dermatitis

Nov. 27, 1998

Continued positive results with fexofenadine in patients with CIU

Nov. 27, 1998

Organogenesis completes patient enrollment in Apligraf diabetic foot ulcer trial

Nov. 19, 1998

Positive phase III clinical trial results received for Olux

Nov. 12, 1998

Team from Angiotech demonstrates paclitaxel's potential as an antipsoriatic

Nov. 12, 1998

Idec Pharmaceuticals: Q3 1998 highlights

Nov. 4, 1998

AlloDerm used to successfully treat rare congenital condition in newborn

Nov. 3, 1998

Aminoacyl sulfamides synthesized at Cubist claimed for psoriasis

Nov. 2, 1998

ICN obtains rights to Senetek skincare cosmeceutical

Oct. 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...